Dexcom ( (DXCM) ) just unveiled an announcement.
On March 6, 2025, Dexcom’s Board of Directors expanded to eleven members with the appointment of Renée Galá as a director. Ms. Galá, recognized for her strategic and financial leadership in the life sciences sector, brings significant expertise to Dexcom, enhancing its potential to drive growth and create shareholder value. Her appointment reflects Dexcom’s strategic focus on expanding its influence in the metabolic health sector, leveraging her experience in global finance and operations.
More about Dexcom
Dexcom, founded in 1999, is a leader in the glucose biosensing industry, providing innovative technology that has transformed diabetes management and glucose tracking, empowering individuals to take control of their health.
YTD Price Performance: -0.84%
Average Trading Volume: 3,621,878
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $30.42B
For an in-depth examination of DXCM stock, go to TipRanks’ Stock Analysis page.